阜外心肌病诊治进展英_第1页
阜外心肌病诊治进展英_第2页
阜外心肌病诊治进展英_第3页
阜外心肌病诊治进展英_第4页
阜外心肌病诊治进展英_第5页
已阅读5页,还剩22页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

Advancementofdiagnosisandtherapyincardiomyopathies

心肌病诊治进展

LIAOYu-HuaInstituteofCardiology,UnionHospital,TongjiMedicalCollegeofHuazhongUniversityofScienceandTechnology,Wuhan,China精选课件ContemporaryDefinitionsandClassificationoftheCardiomyopathies

(2006AHA)

Cardiomyopathiesareaheterogeneousgroupofdiseasesofthemyocardiumassociatedwithmechanicaland/orelectricaldysfunctionthatusually(butnotinvariably)exhibitinappropriateventricularhypertrophyordilatationandareduetoavarietyofcausesthatfrequentlyare

genetic.Cardiomyopathieseitherareconfinedtotheheartorarepartofgeneralizedsystemicdisorders,oftenleadingtocardiovasculardeathorprogressiveheartfailure–relateddisability.MaronBJ,etal.Circulation,2006,113:1807-1816精选课件ClassificationCardiomyopathiescanbemosteffectivelyclassifiedasprimary:

genetic,mixed(geneticandnongenetic),acquired;and

secondaryPrimarycardiomyopathiesarethosesolelyorpredominantlyconfinedtoheartmuscleandarerelativelyfewinnumberSecondary

cardiomyopathiesshowpathologicalmyocardialinvolvementaspartofalargenumberandvarietyofgeneralizedsystemic(multiorgan)disordersMaronBJ,etal.Circulation,2006,113:1807-1816精选课件MaronBJ,etal.Circulation,2006,113:1807-1816精选课件DilatedCardiomyopathyDilatedformsofcardiomyopathyarecharacterizedbyventricularchamberenlargementandsystolicdysfunctionwithnormalLVwallthickness;usuallydiagnosisismadewith2-dimensionalechocardiographyDCMisacommonandlargelyirreversibleformofheartmusclediseasewithanestimated

prevalenceof1:2500;itisthethirdmostcommoncauseofheartfailureandthemostfrequentcauseofhearttransplantationMaronBJ,etal.Circulation,2006,113:1807-1816精选课件DCMphenotypewithgeneticoccurrencAbout20%to35%ofDCMcaseshavebeenreportedasfamilial,althoughwithincompleteandage-dependentpenetrance,andlinkedtoadiversegroupof20lociandgenes.DCMisalsocausedbyanumberofmutationsinothergenesencodingcytoskeletal/sarcolemmal,nuclearenvelope,sarcomere,andtranscriptionalcoactivatorproteins.ThemostcommonoftheseprobablyisthelaminA/Cgene,alsoassociatedwithconductionsystemdisease,whichencodesanuclearenvelopeintermediatefilamentprotein.MaronBJ,etal.Circulation,2006,113:1807-1816精选课件DCMphenotypewithsporadicoccurrenceInfectiousagents,particularlyviruses(coxsackievirus,adenovirus,parvovirus,HIV);bacterial;fungalrickettsial;myobacterial;andparasiticOthercausesincludetoxins;chronicexcessiveconsumptionofalcohol;chemotherapeuticagents;metalsandothercompounds;autoimmuneandsystemicdisorders;pheochromocytoma;neuromusculardisorderssuchasDuchenne/BeckerandEmery-Dreifussmusculardystrophies;andmitochondrial,metabolic,endocrine,andnutritionaldisordersMaronBJ,etal.Circulation,2006,113:1807-1816精选课件Criteria

①leftventricularend-diastolicdimension(LVEDd)>2.7cm/m2②leftventricularejectionfraction(LVEF)<45%and/orfactionalshortening

<25%

Exclusion:①hypertension,②CHD,③long-termoverdosedrinkingalcohol,④persistencesupraventriculararrhythmia,⑤systemicdisease,⑥pericardialdisease,⑦congenitalheartdisease,⑧pneumocardialdisease

DiagnosticcriteriaofidiopathicdilatedcardiomyopathyManolioTA,etal.AmJCardiol,1992,69:1459–66精选课件①diagnosticcriteriaofdilatedcardiomyopathy②Thediagnosisoffamilialdilatedcardiomyopathyis

made:1.inthepresenceoftwoormoreaffectedindividualsinasinglefamily2.orinthepresenceofafirst-degreerelativeofadilatedcardiomyopathypatient,withwelldocumentedunexplainedsuddendeathat<35yearsofageDiagnosis

offamilialdilatedcardiomyopathyMestroniL,etal.

EuroHeartJ,1999,20:93–102精选课件①diagnosticcriteriaofdilatedcardiomyopathy

②immunologicmarkers—anti-heartantibodiesaremainmarkers1including:anti-ANTAb、anti-ß1-receptorAb、anti-MHCAb、anti-M2-receptorAb

Secondarymarkersincluding:

persistentviralinfectionTh2cellpredominancecytokinesgenetypeofhumamleucocyteantigenDiagnosis

ofimmune

dilatedcardiomyopathy

1苑海涛,廖玉华等.临床心血管病杂志,2000,16:313-315精选课件AnalysisofautoantibodyindilatedcardiomyopathyANT31*(64.6%)4(8.3%)64.6%91.7%β126*(54.2%)4(8.3%)54.2%91.7%M220*(41.7%)3(6.3%)41.7%93.7%MHC23*(47.9%)2(4.2%)47.9%95.8%

positiveofautoantibodyinDCM

AHAinDCMPeptides

DCMgroup

(n=48)

HDgroup

(n=48)

sensitivity

specificity

n(%)n(%) ComparedwithHDgroup*p<0.005苑海涛,廖玉华.临床心血管病杂志,2000,16:313精选课件ImmunopathogenesisinDCMVoltage-gatingCa-channelsCa-overloadCelldamageCardiacdilationReceptor-gatingCa-channelsVirusinfectionandautoimmunityresponseDCMAnti-ANT-AbAnti-ß1-RAb精选课件TreatmentofDCM1、Conventionaltreatmentofheartfailure2、Preventembolism3、PreventSCD4、Improvecardiacmetabolism5、Cardiacresynchronizationtherapy6、Cardiactransplantation7、ImmunologictherapyinDCM精选课件1.β-receptorblockerToinhibittheanti-β1-Abmediatedmyocardiualdamage,especiallyinearlystageEspeciallysuitforthepatientswithtachycardiaorventriculararrhythmias,orwithanti-β1-AbpatientsDose:metroprolol6.25mgBidto12.5~100mgBid,slowlytitrateBlockedautoantibodiesresponse(1)精选课件

MDCtrial

Patients345,MGn=177andPGn=16816-75yearsofage

Metoprolol10mg/day→100~150mg/day

therapyofHF:digitalis、diuretics、ACEI

Followingup18months

MetoprololisindicatedtoimprovequanlityoflifeinheartfailurewithDCMβ-receptorblocker

clinicaltrialinDCMWaagsteinF,etal.Lancet,1993,342:1441-46

精选课件2.DiltiazemFrequeceofAnti-ANTantibodyispositiveabout60%-95%Mechanism:Anti-ANTantibodyincreasedCacurrentofmyocardialcell.DiltiazemcouldinhibittheantibodymediatedmyocardialdamageandprotectmyocardiumDiltiazemmightbeusedinearlystageofDCMDosage:diltiazem30mgtid

Blockedautoantibodiesresponse

(2)精选课件CalciumantagonistclinicaltrialinDCMDiDitrialPatients186,DGn=92andPGn=9418~70yearsofagetheadjuncttherapyofdiltiazem60~90mgtidonstandardtreatmentDiDitrialisshowedtoimprovecardiacfunction,exercisecapacityandsubjectivestatusinDCMFigullaHR.Circulation,1996,94:346-352.精选课件CalciumantagonistclinicaltrialinDCMISDDCtrialToevaluateeffectsofdiltiazemonheartfunctionandprognosisinDCMMultiplecentre,random,placebo-control

Followingup6~12monthsPatients221,PGn=107andDGn=114,46±12yearsofageDiltiazem60~90mg/dayorVitB160mg/day

TherapyofHF:digoxine,diuretics,ACEILiaoYH.IntJCardiol,1998,64:25-30.精选课件ISDDCtrial

PrognosisanalysisinDCM

PlaceboDiltiazemn=107n=114Outpatienttreatment63(58.9)102(89.5)***

Repeatedhospitalization44(41.1)12(10.5)***Death12(11.2)4(3.5)**Comparedwithplacebogroup**p<0.05,***p<0.01LiaoYH.IntJCardiol,1998,64:25-30.精选课件

BeforeAfterLVEDd>70mm(n=28)

LVEDd77.61±5.3874.50±8.92*

EF27.68±11.6933.71±12.64*

LVEDd<70mm(n=86)

LVEDd61.34±4.9156.88±5.32**

EF38.76±8.7546.07±7.88**

Comparedwithbeforetreatment,*p>0.05,**p<0.01

ISDDCtrialSubgroupanalysisofheartfunctionLiaoYH.IntJCardiol,1998,64:25-30.精选课件HeartimageafterdiltiazemtreatedDCM2000-8-11CTR0.451999-1-18CTR0.51998-9-17CTR0.6精选课件ISDDCtrialconclusionLiaoYH.IntJCardiol,1998,64:25-30.diltiazemissafeandeffectiveinthetreatmentofDCMtheactionmechanismmightbeinterventioninantibody-mediatedmyocardialdamageandprotectionofmyocardiumdiltiazemismoresuitablefortreatmentof

theearlystageinDCM

精选课件PathogenesisandtreatmentinDCMß1-blocksDiltiazemVoltage-gatingCa-channelsCa-overloadCelldamageCardiacdilation

Receptor-gatingCa-channelsVirusinfectionandautoimmunityresponseAnti-ANT-AbAnti-ß1-RAbTherapyofHFDCMHFnoHFSevereHFLiaoYH.2001精选课件ImmunoadsorptionofautoantibodiesAnti-β1-adrenoceptorantibodyremovedbyimmunoadsorptioninpatientswithDCM,meanwhiletreatmentofheartfailureFollow-uponeyear,LVEFincreasing15%(22.3±3.3%to37.9±7.9%)

andLVEDddecreasing14.5%(74.5±7.1to63.7±6.0mm)inDCMgroup;LVEF(23.8±3.0to25.2±5.9%)noimprovement

andLVEDddecreased3.8%incontrolgroupTheclinicaltrialconfirmedthatremovingtheautoantibodiesmightimproveheartfunctioninDCMMüllerJ,etal.Circulation,2000,101:385-39SchimkeI,etal.JClinApher,2005,20:137-42精选课件ImmunomodulatingtherapyImmunomodulatingtherapywithintravenousimmunoglobulin2g/kginpatientswithchronicheartfailurewithin6monthsrecentlydiagnosedDCMAftertreated6monthsand12months,LVEFincreasing(0.25±0.08to0.41±0.17/6monthand0.42±0.14/12month)inpatientswithDCMThefindingsuggestsimmunoglobulinmight

regulatethebalanceofinflammatoryfactorand

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论